ReCor Medical Discloses New Data From Clinical Study of its PARADISE™ Ultrasound Transcatheter Renal Denervation System for Treating Resistant Hypertension

Published: Apr 09, 2012

RONKONKOMA, N.Y.--(BUSINESS WIRE)--ReCor Medical, an emerging medical device company, disclosed today updated data for the REDUCE First-In-Man clinical study of its PARADISE (Percutaneous Renal Denervation System) ultrasound platform for achieving renal denervation. PARADISE, which is CE-marked, is designed to treat patients with ‘resistant’ hypertension (“HTN”), a major risk factor for cardiovascular disease.

Back to news